Table 3.
Logistic regression analysis for risk factors for PTDM.
| Univariable | Multivariable | |||
|---|---|---|---|---|
| OR (95% CI) | p-Value | OR (95% CI) | p-Value | |
| Gender (vs. female) | ||||
| Male | 1.33 (0.84–2.13) | 0.23 | 1.30 (0.76–2.21) | 0.33 |
| Age at KT, years (vs. <45 years) | ||||
| 45–65 | 2.62 (1.60–4.29) | <0.001 ** | 2.90 (1.64–5.13) | <0.001 ** |
| >65 | 3.38 (1.17–9.80) | 0.03 * | 4.86 (1.50–15.79) | 0.008** |
| Donor source (vs. living) | ||||
| Cadaveric | 2.30 (1.29–4.07) | 0.004 ** | 2.01 (1.03–3.93) | 0.040 * |
| BMI, kg/m2 (vs. BMI <24) | ||||
| 24–27 | 2.75 (1.53–4.92) | 0.001 ** | 2.96 (1.52–5.75) | 0.001 ** |
| >27 | 4.15 (2.32–7.44) | <0.001 ** | 5.35 (2.75–10.42) | <0.001 ** |
| IMR groups (vs. FK-based) | ||||
| FK + mTORi | 0.39 (0.22–0.70) | 0.002 ** | 0.28 (0.14–0.55) | <0.001 ** |
| CsA | 2.14 (0.86–5.33) | 0.10 | 1.40 (0.49–3.97) | 0.53 |
| CsA + mTORi | 0.41 (0.09–1.85) | 0.25 | 0.30 (0.06–1.64) | 0.17 |
* p < 0.05, ** p < 0.01. PTDM: post-transplant diabetes mellitus; BMI: body mass index; KT: kidney transplantation; IMR: immunosuppressive regimen; FK: tacrolimus; mTORi: mammalian target of rapamycin inhibitor; CsA: cyclosporine.